Pemvidutide

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Pemvidutide?

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist developed by Altimmune (now acquired by Novo Nordisk’s obesity pipeline network). Unlike single-target GLP-1 agonists such as semaglutide, pemvidutide simultaneously activates both the GLP-1 receptor and the glucagon receptor, aiming to combine appetite suppression with glucagon-mediated increases in energy expenditure and hepatic fat reduction.[1][2]

Pemvidutide has generated significant clinical interest through phase 2 trials in both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), with the Lancet publishing results from the IMPACT trial in December 2025. The dual-agonist approach positions pemvidutide alongside tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon) as part of the multi-receptor agonist class.[1][3]

Compound Profile

What Does Pemvidutide Actually Do?

Pemvidutide combines two pharmacological actions through dual receptor activation. GLP-1R agonism suppresses appetite and improves glycaemic control (the mechanism shared with semaglutide), while glucagon receptor agonism increases hepatic lipid oxidation, energy expenditure, and preferentially reduces liver fat.[1][2]

The IMPACT phase 2b trial published in The Lancet demonstrated that pemvidutide achieved significant weight loss and improvements in hepatic steatosis in patients with MASH. At 24 weeks, pemvidutide produced clinically meaningful reductions in liver fat content and improvements in markers of liver fibrosis — addressing a disease where effective pharmacological treatments remain limited.[1]

How Pemvidutide Works

Pemvidutide’s dual mechanism creates complementary metabolic effects through two distinct receptor pathways:[2][3]

GLP-1 receptor activation: Reduces appetite through hypothalamic signalling, enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety. This component drives the weight loss and glycaemic improvement seen with all GLP-1 agonists.

Glucagon receptor activation: Stimulates hepatic fatty acid oxidation and ketogenesis, increases resting energy expenditure, and promotes liver fat mobilisation. Glucagon’s catabolic effects on liver fat complement GLP-1’s appetite-suppressive effects, potentially producing greater hepatic steatosis reduction than GLP-1 agonism alone.

The rationale for dual agonism is that glucagon’s metabolic effects — increased energy expenditure and liver fat reduction — address aspects of metabolic disease that GLP-1 agonism alone does not optimally target. The challenge is balancing glucagon’s hyperglycaemic effects with GLP-1’s glucose-lowering activity, which pemvidutide achieves through calibrated receptor activation ratios.

Pemvidutide’s once-weekly injection profile is achieved through fatty acid acylation (similar to semaglutide’s albumin-binding approach), extending plasma half-life through reversible albumin binding.

Appetite & Weight Management Context

Pemvidutide’s clinical data positions it within the appetite and weight management research landscape as a next-generation multi-agonist. Phase 2 obesity trial data showed significant weight loss, with the dual GLP-1/glucagon mechanism theoretically offering advantages over pure GLP-1 agonism through additional energy expenditure stimulation.[2][4]

A key question is whether the glucagon component provides meaningful additional weight loss beyond what GLP-1 agonism alone achieves. Early data suggests the contribution is present but modest compared to the appetite-suppressive effects of GLP-1R activation. The primary differentiator may be body composition — glucagon’s preferential mobilisation of liver and visceral fat could produce metabolically superior weight loss even at similar total weight reduction.[1]

Compare with semaglutide (GLP-1 only), tirzepatide (GIP/GLP-1), and retatrutide (triple GLP-1/GIP/glucagon), or see the Appetite & Weight Management goal page.

Metabolic Health / Insulin Sensitivity Context

The MASH indication places pemvidutide squarely within the metabolic health context. MASH — the inflammatory stage of fatty liver disease — has no approved pharmacological cure, making effective treatments a major unmet medical need. Pemvidutide’s glucagon-mediated liver fat reduction directly targets the pathological process driving MASH progression.[1][3]

The Lancet-published IMPACT trial demonstrated significant reductions in hepatic steatosis and improvements in fibrosis markers at 24 weeks. A GRADE-assessed meta-analysis confirmed pemvidutide’s efficacy and safety profile in the MASH population, providing systematic evidence synthesis beyond individual trial results.[5]

Glycaemic effects reflect the balanced dual agonism — GLP-1’s glucose-lowering activity offsets glucagon’s hyperglycaemic tendency, resulting in net-neutral to mildly improved glucose control in most patients. See the Metabolic Health goal page for broader context.

Fat Loss & Recomp Context

Pemvidutide’s glucagon component adds a fat loss-relevant dimension beyond pure appetite suppression. Glucagon receptor activation stimulates hepatic lipid oxidation and increases resting energy expenditure, potentially producing preferential fat mass reduction compared to agents that reduce weight primarily through caloric restriction.[2]

Concerns about muscle loss during pharmacological weight loss have been raised across the GLP-1 agonist class. Whether pemvidutide’s dual mechanism produces a more favourable fat-to-lean mass loss ratio compared to GLP-1-only agents is an active research question. The increased energy expenditure from glucagon agonism theoretically favours fat oxidation, but clinical body composition data is limited.[6]

See the Fat Loss & Recomp goal page for broader context.

Pemvidutide Benefits

• Dual mechanism: Simultaneous GLP-1 and glucagon receptor activation provides complementary metabolic effects — appetite suppression plus increased energy expenditure and liver fat reduction.[1][2]
• Lancet-published MASH data: Phase 2b results in MASH showed significant hepatic steatosis reduction and fibrosis improvement — addressing a major unmet medical need.[1][3]
• Weekly injection: Once-weekly subcutaneous dosing provides convenient administration comparable to semaglutide.
• Preferential liver fat reduction: Glucagon-mediated hepatic lipid oxidation may produce metabolically superior outcomes compared to weight loss from appetite suppression alone.[2]
• Energy expenditure increase: Glucagon agonism stimulates resting energy expenditure, a mechanism not present in pure GLP-1 agonists.[2]

Pemvidutide Side Effects

Phase 2 clinical trial data provides safety characterisation:

• Gastrointestinal effects: Nausea, vomiting, and diarrhoea were the most common adverse events — consistent with the GLP-1 agonist class. Rates were generally manageable with dose titration.
• Appetite reduction: Significant appetite suppression, while therapeutically desirable, can be excessive at higher doses.
• Glycaemic effects: The glucagon component’s hyperglycaemic tendency is partially offset by GLP-1’s glucose-lowering effect, but monitoring is needed in diabetic patients.
• Heart rate effects: Small increases in heart rate have been observed, consistent with GLP-1 agonist class effects.
• Limited long-term data: Phase 2 trial durations (24 weeks) do not capture potential long-term safety signals.

Half-Life

Pemvidutide has a plasma half-life supporting once-weekly subcutaneous injection, achieved through fatty acid acylation that promotes reversible albumin binding in circulation. This pharmacokinetic approach is analogous to the half-life extension strategy used in semaglutide. Exact half-life values from pharmacokinetic studies have been characterised in the clinical pharmacokinetics literature.[7]

Limits of Current Evidence

• No phase 3 data: While phase 2b results are promising and Lancet-published, phase 3 trials are needed for regulatory submission and to confirm findings in larger populations.
• Short trial duration: 24-week data does not capture durability of effect, potential for treatment resistance, or long-term safety.
• Body composition data limited: Whether the glucagon component truly produces superior fat-to-lean mass loss ratios requires more detailed body composition studies.[6]
• Competitive landscape pressure: Pemvidutide enters a rapidly expanding market with semaglutide, tirzepatide, and retatrutide — distinguishing itself commercially requires clear clinical advantages.
• MASH endpoint debate: Surrogate endpoints (liver fat, fibrosis markers) used in phase 2 MASH trials may not predict hard clinical outcomes (cirrhosis prevention, liver transplant reduction).

Verdict

Pemvidutide occupies a compelling position in the multi-agonist peptide landscape — a dual GLP-1/glucagon agonist with Lancet-published phase 2b data in one of medicine’s most significant unmet needs (MASH). The glucagon component provides a pharmacologically rational addition to GLP-1 agonism, targeting liver fat metabolism and energy expenditure in ways that single-target agents do not.

The clinical evidence supports both weight management and hepatic steatosis applications, with the MASH indication arguably offering the clearest competitive differentiation. Whether pemvidutide can secure a distinct clinical niche against the formidable competition from tirzepatide and retatrutide depends on phase 3 results, particularly in MASH-specific hard endpoints and body composition outcomes.

FAQ

What is pemvidutide?

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist — a once-weekly injectable peptide that simultaneously activates both the GLP-1 receptor (reducing appetite) and the glucagon receptor (increasing energy expenditure and liver fat oxidation). It has completed phase 2b trials in obesity and MASH.

How does pemvidutide differ from semaglutide?

Semaglutide activates only the GLP-1 receptor. Pemvidutide activates both GLP-1 and glucagon receptors. The glucagon component adds hepatic fat reduction and increased energy expenditure — effects not produced by GLP-1 agonism alone. Both are once-weekly injectable peptides.

What is pemvidutide used for?

Pemvidutide is being investigated for obesity/weight management and for metabolic dysfunction-associated steatohepatitis (MASH/NASH). The Lancet-published IMPACT trial focused on the MASH indication, showing significant liver fat reduction and fibrosis improvement. Pemvidutide is not yet approved for any indication.

What are pemvidutide side effects?

The most common side effects in clinical trials were gastrointestinal (nausea, vomiting, diarrhoea) — consistent with GLP-1 agonist class effects. Small heart rate increases and appetite reduction were also observed. Long-term safety beyond 24 weeks has not been characterised.

Is pemvidutide approved?

No. Pemvidutide has completed phase 2b clinical trials but has not been approved by any regulatory agency. Phase 3 trials would be needed for regulatory submission. Results from the IMPACT trial were published in The Lancet in December 2025.

How does pemvidutide compare to tirzepatide?

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist, while pemvidutide is a dual GLP-1/glucagon agonist. They use different second receptors: tirzepatide adds GIP (which enhances insulin secretion), pemvidutide adds glucagon (which increases energy expenditure and liver fat oxidation). Tirzepatide is approved and has more extensive clinical data.

References

1. Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results of a randomised, double-blind, phase 2b trial. Lancet. 2025. PMID: 41237796
2. Anderson SL, et al. Emerging concepts in obesity management: focus on pemvidutide. Drugs Context. 2025. PMID: 40734920
3. Tacke F, et al. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025. PMID: 41352959
4. Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. PMID: 39002641
5. Rajab I, et al. Efficacy and safety of pemvidutide in MASH: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 41879841
6. von Haehling S, et al. Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. J Cachexia Sarcopenia Muscle. 2025. PMID: 41362110
7. Nordell P, et al. Systemic Pharmacokinetic Principles of Therapeutic Peptides. Clin Pharmacokinet. 2026. PMID: 41661442